Besifloxacin in Bacterial Keratitis

• Status: Unknown status
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study comparing a new treatment for bacterial keratitis (also known as corneal ulcers) with the current standard of care. It is a randomized trial, and the investigators plan to test whether besifloxacin (a new antibiotic) in comparison to the current standard of treatment, fortified antibiotic drops (cefazolin and tobramycin).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Besifloxacin; Cefazolin; Fluoroquinolones; Tobramycin

Criteria

Inclusion Criteria:

• • Provide signed and dated informed consent form

• Willing to comply with all study procedures and be available for the duration of the study

• Male or female, aged 18 or older

• Clinically diagnosed bacterial keratitis, with any size ulcer > 1mm.

Exclusion Criteria:

• • Previously treated for current episode of bacterial keratitis with an antibiotic drop

• Corneal Ulcers <1mm

• Known allergic reaction to components of the study products